Danish and American industry leaders will meet in Boston on 17 November for detailed discussions on bio-defense. Denmark has a number of companies and academic groups developing cutting edge bio-defense products including vaccines, anti-infective agents, detection and cleanup technologies. The Danish Ministry of Foreign Affairs, Invest in Denmark and Copenhagen Capacity are organizing the meeting which will explore collaborative opportunities for developing bio-defense products.
The purpose of the meeting is to increase awareness in the US of the advanced state of the bio-defense industry in Denmark in order to facilitate downstream collaboration and alliances between US and Danish parties. The meeting will also provide an opportunity for key figures from the industry to exchange ideas and solutions with their US colleagues.
Speakers will include Peter Wulf, CEO, Bavarian Nordic (www.bavarian-nordic.com), Dr Una S. Ryan OBE, President & CEO, AVANT Immunotherapeutics (www.avantimmune.com), Dr Robert Hopkins, V.P. Clinical Research, DynPort Vaccine (www.dynport.com), John Haurum, CSO, Symphogen (www.symphogen.com), Kevin Price, Commercial Director, AVECIA Biotechnology (www.avecia.com) and Jacob Jacobsen, Director Business Development, ACE Biosciences (www.acebiosciences.com).
The biotechnology sector is well developed in Denmark due to robust governmental support, an entrepreneurial environment, an active venture capital market and a world-class pharma sector. Denmark has a very stable economy with flexible labor laws, competitive corporate tax laws, a favorable tax regime for holding companies in Europe and a generally low cost structure.
For further information please contact Gitte Pedersen on (212) 665 8626 or e-mail email@example.com